Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17658901 | 0.89 | TP53BP1 (0.61) | TP53BP1KMT2AGAAHSD17B10GPR139 | |
| SCHEMBL23034573 | 0.80 | TP53BP1 (0.46) | TP53BP1KMT2AGAAHSD17B10GPR139 | |
| SCHEMBL12756951 | 0.79 | NPC1 (0.61) | KMT2AGAAHSD17B10SMN1; SMN2CTSL | |
| SCHEMBL19123098 | 0.79 | SMN1; SMN2 (0.46) | KMT2AGAAHSD17B10SMN1; SMN2L3MBTL1 | |
| SCHEMBL3744859 | 0.77 | SMN1; SMN2 (0.51) | KMT2AGAAHSD17B10SMN1; SMN2L3MBTL1 | |
| SCHEMBL20350321 | 0.77 | SMN1; SMN2 (0.51) | TP53BP1KMT2AGAAHSD17B10SMN1; SMN2 | |
| SCHEMBL19116694 | 0.77 | TP53BP1 (0.47) | TP53BP1KMT2AGAAHSD17B10GPR139 | |
| SCHEMBL7126373 | 0.76 | TP53BP1 (0.57) | TP53BP1KMT2AGAAHSD17B10SMN1; SMN2 | |
| SCHEMBL960413 | 0.76 | L3MBTL1 (0.68) | TP53BP1KMT2AGAASMN1; SMN2L3MBTL1 | |
| SCHEMBL16136527 | 0.76 | SMN1; SMN2 (0.46) | TP53BP1KMT2AGAAHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TP53BP1 3917/4885KMT2A 3837/4885GAA 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.